# Annexin A5 in Patients With Severe COVID-19 Disease

> **NCT04748757** · PHASE2 · COMPLETED · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 18 (actual)

## Conditions studied

- Coronavirus Infection
- Sepsis

## Interventions

- **DRUG:** recombinant human annexin A5
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04748757
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2022-04-03
- **Final completion:** 2022-12-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04748757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04748757, "Annexin A5 in Patients With Severe COVID-19 Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04748757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*